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Accelerated age-related olfactory 
decline among type 1 Usher 
patients
João Carlos Ribeiro1,2,3, Bárbara Oliveiros2,3, Paulo Pereira2,3, Natália António2, 
Thomas Hummel4, António Paiva1,2 & Eduardo D. Silva2,3
Usher Syndrome (USH) is a rare disease with hearing loss, retinitis pigmentosa and, sometimes, 
vestibular dysfunction. A phenotype heterogeneity is reported. Recent evidence indicates that USH 
is likely to belong to an emerging class of sensory ciliopathies. Olfaction has recently been implicated 
in ciliopathies, but the scarce literature about olfaction in USH show conflicting results. We aim to 
evaluate olfactory impairment as a possible clinical manifestation of USH. Prospective clinical study 
that included 65 patients with USH and 65 normal age-gender-smoking-habits pair matched subjects. 
A cross culturally validated version of the Sniffin’ Sticks olfaction test was used. Young patients with 
USH have significantly better olfactory scores than healthy controls. We observe that USH type 1 have 
a faster ageing olfactory decrease than what happens in healthy subjects, leading to significantly lower 
olfactory scores in older USH1 patients. Moreover, USH type 1 patients showed significantly higher 
olfactory scores than USH type 2, what can help distinguishing them. Olfaction represents an attractive 
tool for USH type classification and pre diagnostic screening due to the low cost and non-invasive 
nature of the testing. Olfactory dysfunction should be considered among the spectrum of clinical 
manifestations of Usher syndrome.
Usher syndrome (USH) is a heterogeneous, rare, multisystemic genetic disease, characterized by sensorineural 
hearing loss, retinitis pigmentosa (RP), and variable vestibular dysfunction. Its prevalence ranges from 3 to 8.0 
per 100,000 people1.
Patients with Usher syndrome (USH) often display a complex array of signs and symptoms. The visual, audi-
tory, and vestibular manifestations are well documented, while additional manifestations of the condition have 
not received much attention. USH is classified into three clinical types2. USH type 1 (USH1) is associated with 
severe-to-profound sensorineural congenital deafness, vestibular areflexia, and prepuberal onset of RP. USH type 
2 (USH2) is characterized by moderate-to-severe hearing impairment, no vestibular impairment, and onset of RP 
in the first or second decade of life. In type 3 (USH3), the least prevalent type of USH, the post lingual hearing loss 
onset is progressive while RP and vestibular dysfunction onset is variable3.
While auditory and vestibular testing helps to differentiate among USH types, overlapping and atypical pres-
entations have been described for all three types of Usher syndrome4–8. Specific genetic patterns are associated 
with each USH phenotype, even while genetic heterogeneity has been reported9. A genotype-phenotype corre-
lation would help to guide genetic evaluation or even make it unnecessary if a perfect correlation is achieved. 
Next generation sequencing provides a useful tool to reveal clinical misdiagnosis, identify late onset syndromic 
features, establish novel genotype/phenotype correlations, and to facilitate clinical diagnosis10,11. Yet, our group 
has observed 10% of cases manifesting atypical presentations (unpublished data).
Improving phenotype may help improving USH diagnosis and genotype-phenotype correlation. Olfaction may 
be an important link in USH. Nevertheless, very few papers studied olfaction in patients with USH. Seeliger et al.12 
studied 8 USH1 and 31 USH2 patients with Sniffin’ Sticks test13. Although no significant olfactory differences were 
found, it is interesting to observe that patients with USH1 were 20–40 years old and showed a median olfactory 
score higher than control group (9.7 vs 8.5). They also found a far more rapid decline in olfactory threshold of 
USH1 that was not explained by normal ageing. Zrada et al.14 observed 22 patients (8 USH1 and 22 USH2), by 
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means of UPSIT age- gender- smoking-habit- matched controls15. Olfactory thresholds were higher than those of 
controls, although statistical significance was not attained, probably because the study was not adequately powered. 
In another study, Marietta et al.16 studied the olfactory acuity in a subgroup of USH1C patients. They used UPSIT 
test in 18 older patients, not pair matched. Although an age decline in olfaction appeared to be greater than nor-
mative data, the difference was not significant16.
Patients with ciliopathies affecting the inner ear are frequently deaf and/or persons who exhibit balance difficul-
ties; and patients with retinal ciliopathies often become blind17. Genetics, biochemistry and proteomic approaches 
have demonstrated that USH proteins are organized in networks in both the eye and the inner ear18. Consequently, 
a disease that have both systems affected like USH is expectable to be a sensory ciliopathy18. Furthermore, 
USH has been associated with bronchiectasis, chronic sinusitis, reduced nasal mucociliary clearance19,20  
and altered sperm function21, all of which are suggestive of ciliary dyskinesia19.
In recent years a number of papers helped to elucidate the relationship between olfaction and its genetic 
underpinnings since the pioneering work of Buck and Axel, 199122. Because recent evidence implicated olfaction 
in sensory ciliopathies18,23–28, it is expectable that olfaction is also implicated in USH, however, the few previous 
studies addressing functional olfactory acuity in patients with USH have showed conflicting results12,14,29.
AIM
Knowing that Usher syndrome is a ciliopathy from a histopathological and molecular standpoint, we have under-
taken a prospective recruitment of patients with USH to study their functional olfactory features. This study 
aimed at identifying and characterizing putative differences in olfactory capacity between patients with USH and 
controls, as well as among the subtypes of USH.
Patients and Methods
All participants provided informed written consent. The study followed the Declaration of Helsinki 2013 on 
Biomedical Research Involving Human Participants and was approved by the Ethics Committee of the Faculty of 
Medicine, University of Coimbra, Portugal.
Sixty-five patients with USH (49.2 ± 15.1 years old; 18 females and 47 males) were prospectively recruited 
from the Otorhinolaryngology consultation of the Centro Hospitalar e Universitário de Coimbra, Portugal. They 
were pair-matched with 65 healthy controls (controls 49.2 ± 14.9 years old) for age, sex, and smoking habits, so 
that a total of 130 participants were studied.
All participants received a full ENT clinical examination, as well as a structured interview, a rhinologic exam-
ination including nasal endoscopy and a standardized Sniffin’ Sticks test (Burghart GmbH, Wedel, Germany) 
culturally validated to the Portuguese population (SnSt-pt)30. Briefly, this test comprised three subtests, namely 
odor threshold (T, tested by means of a single staircase procedure), odor discrimination (D, 3-alternative forced 
choice) and odor identification (I, 4-alternative forced choice). Results of the 3 subtests are typically summed up 
and presented as a composite TDI score, as review by Hummel et al.31.
Eligible patients had a documented neurosensory hearing loss and RP, fulfilling the clinical criteria for USH1 
or USH2, as defined by the USH consortium2. Exclusion criteria included participants with known factors affect-
ing olfaction, such as post-traumatic olfactory dysfunction, sinonasal disease, malignant tumor, recent radiother-
apy or chemotherapy, post-upper respiratory tract infection, use medication known to interfere in olfaction32, and 
Parkinson´s and Alzheimer´s disease.
Statistical analysis of the data was performed using the Statistical Package for the Social Sciences (SPSS), version 
22.0 (SPSS, Inc., Chicago, IL). The normality of continuous variables was tested with the Kolmogorov-Smirnov 
test. Age is displayed as mean and standard deviation. Olfactory data is presented as median and interquartile 
range. The Mann-Whitney U test or Student’s t-test test was used whichever appropriate. In spite of the main 
measure being the Sniffin’ Sticks TDI scores, and though it would be justifiable not to perform multiple compar-
isons adjustment in planned comparisons using each one of the partial measures (T, D, and I sub-scales of the 
Sniffin’ Sticks TDI scale), the fact is that those sub-scales are not perfectly independent. As a result, the multiple 
comparisons problem arises, and is sorted out through the Holm’s correction, which controls the Family-Wise 
Error Rate, and the Benjamini-Hosper correction, which controls the False Discovery Rates. Spearman´s rank 
correlation coefficient was calculated to verify the relationship between subgroups tested for olfaction. Multiple 
linear regression with previous bootstrapping was used to correlate olfaction in relation to age and Usher subtype. 
All tests were two-tailed and statistical significance was accepted at the p < 0.05 level.
Results
Sixty-five USH patients (49.2 ± 15.1 years old; 18 females/47 males) were pair-matched with 65 healthy controls 
(49.2 ± 14.9 years old; 18 f/47 m).
Patients with USH included 22 USH1 (43.4 ± 16.7 [18–77] years old; 5 f/17 m) that were compared to 22 
healthy pair matched controls (43.3 ± 16.1 years old; 5 f/17 m), and another 43 USH2 (52.2 ± 13.5 years old; 13 
f/30 m) that were pair matched to 43 healthy controls (52.2 ± 13.5 [32–78] years old; 13 f/30 m).
Total USH patients’ vs controls. USH patients′ olfactory scores were compared to pair matched con-
trols. Patients with USH had significantly better SnSt- composite TDI olfaction scores than healthy controls (32.8 
[28.5–37.4]) vs (30.0 [28.6–31.3]), (p = 0.002). Both USH1 and USH2 showed better discrimination scores than 
controls, with large standardized effect sizes (Table 1).
USH1 VS USH2. USH1 and USH2 are distinguishable in terms of hearing loss and vestibular function. 
Patients with USH1 and USH2 were compared regarding olfaction capabilities and USH1 showed significantly 
higher TDI and identification scores than USH2 (Table 2). Effect size was 1.27 with a posteriori power of 99.87%.
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Usher syndrome olfactory age decline. A deeper look showed a significant olfactory ageing decline in 
patients with USH. Because olfaction is known to decline with ageing30 and to adequately evaluate how olfac-
tory ability is affected in USH patients, it is important to rule out ageing´s effect on olfaction. Consequently, 
after considering the normal age effect on olfaction based on our normative data30 (n = 203, that compares 
well with original data from Hummel et al.31), a multiple regression model was obtained. Patients with USH 
show a significantly faster age decline in olfaction. This effect is particularly relevant regarding USH1 patients: 
TDI = 50,010 − 0,401 × age; T = 16,549 − 0,188 × age; D = 16,248 − 0,124 × age; and I = 17,096 − 0,127 × age 
(Table 3).
After correcting for normal olfactory ageing decline, patients with USH1 show a significantly faster olfactory 
decline with age than healthy subjects with a R2 = 0.703 and a power of 99.99% (Table 4).
The significant olfactory decline in patients with USH1, not attributable to the olfactory ageing effect, is dis-
played in Fig. 1. Normative data is presented for comparison purposes (Fig. 1).
Considering patients with USH2, none of the models were statistically significant. Olfactory ageing effect is 
presented in Fig. 2.
When comparing patients with USH1 younger or older than the mean age of the group (43 years old), the 
older ones show significantly lower TDI scores (11.9 ± 1.7 vs 4.9 ± 2.0, p < 0.001) (Table 5). Such effect is not seen 
in patients with USH2.
The faster olfactory loss after adjusting for normal age related olfactory loss comparisons achieved a power of 
at least 91.12% in the all comparisons.
Discussion
The present study shows that patients with USH have significantly better TDI scores than healthy controls. 
Moreover, patients with USH1 show significantly higher TDI scores than patients with USH2, what can help to 
phenotypically distinguish them, having important clinical implications. A cut-off age of 43 years could be used. 
We observe that patients with USH1 have a faster decrease in olfactory function than what happens in healthy 
subjects, leading to much lower olfactory scores in older patients with USH1.
Data presented in this study indicates that olfactory tests may provide a valuable tool in characterizing and 
categorizing USH types. Although auditory and vestibular testing helps to distinguish typical USH patients, addi-
tional phenotypic abnormalities are necessary to aid in differentiating among atypical cases. Because of that, the 
current phenotype–genotype correlation is insufficient to predict the likely causative mutation, which makes 
Patients Controls STS p
Holm’s Correction 
(α)
Benjamini-Hosper 
(α)
USH
T 8.3 (5.1–11.0) 7.8 (5.8–8.3) − 1.585 0.113 0.025 0.033
D 11 (9–12) 10 (9–11) −3.416 0.001 0.017 0.017
I 13 (11–14) 13 (12–13) − 0.476 0.634 0.050 0.050
TDI 32.8 (28.5–37.4) 30.0 (28.6–31.3) −3.095 0.002 – –
USH1
T 8.1 (4.6–12.5) 7.9 (5.8–9.4) − 0.646 0.518 0.050 0.050
D 12.5 (9.3–13.8) 9.5 (9–11) −2.212 0.027 0.017 0.017
I 14 (11.3–15) 13 (12–13) − 1.104 0.270 0.025 0.033
TDI 38.5 (28.2–41.1) 30.9 (29.1–32.3) − 1.623 0.105 – –
USH2
T 8.3 (5.5–10.8) 7.5 (5.5–8.3) − 1.794 0.073 0.025 0.033
D 11 (9–12) 10 (9–11) −2.613 0.009 0.017 0.017
I 12 (11–14) 13 (12–13) 0.072 0.943 0.050 0.050
TDI 32.3 (28.8–35) 29.8 (27.5–30.5) −2.856 0.004 – –
Table 1.  Sniffin’ Sticks Portuguese version olfactory test results comparing Usher and Usher type patient’s 
vs controls. STS: Standardized Test Statistic. TDI: composite score of T, D and I. T: threshold; D: discrimination; 
I: Identification. Highlighted differences should be retained as statistically significant differences, according to 
the alpha level presented either by the Holm’s or the Benjamini-Hochberg correction for multiple comparisons.
USH1 USH2 STS p
Holm’s Correction 
(α)
Benjamini-Hochberg 
(α)
T 8.1 (4.6–12.5) 8.3 (5.5–10.8) −4.020 <0.001 0.017 0.017
D 12.5 (9.3–13.8) 11 (9–12) 0.093 0.926 0.050 0.050
I 14 (11.3–15) 12 (11–14) −3.360 0.001 0.025 0.033
TDI 38.5 (28.2–41.1) 32.3 (28.8–35) −4.261 <0.001 – –
Table 2.  Sniffin’ Sticks Portuguese version olfactory test results comparing olfaction between USH1 with 
USH2. STS: standardized test statistic. TDI: composite score of T, D and I. T: threshold test; D: discrimination 
test; I: Identification test. Highlighted differences should be retained as statistically significant differences, 
according to the alpha level presented either by the Holm’s or the Benjamini-Hochberg correction for multiple 
comparisons.
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sequencing of all known USH genes an often necessary but difficult way to identify the underlying genetic defect 
in affected patients.
The few papers addressing olfaction in Usher have shown conflicting results12,14,16,29. Our study tried to solve 
some methodology problems that highly limited the strength of conclusions from those papers. Being a rare 
disease, with such heterogeneous phenotypes, it is difficult to investigate a sample size with a sufficient power to 
confirm possible differences in olfaction among patients with Usher12,14,16. While some papers trust on the sub-
jects’ self-assessment of olfaction, it is unreliable, and testing olfactory function is necessary33. Moreover, some 
previous studies used non-standardized and not validated olfactory testing14. Additionally, because patients were 
not matched for well-known factors to affect olfaction13,34–36 including age, gender and smoking habits12,14,37, 
those studies must be interpreted with caution38.
The better olfaction observed in young USH1 may be easily explained by the adaptive intramodal neuroplas-
ticity and cross-modal sensory reorganization associated with blindness and by the behavioral compensations 
taking place in the remaining senses, including those in the tactile, auditory and olfactory domains39–42. Recent 
studies on olfaction in blind persons have shown that early blindness may affect olfactory processing39,41,43–45. Not 
Correlation Regression
Coefficient P Coefficient 95% confidence interval p
T − 0.792 < 0.001 −0.188 − 0.268 a − 0.134 0.001
D − 0.824 < 0.001 −0.124 − 0.192 a − 0.093 0.002
I − 0.842 < 0.001 −0.127 − 0.175 a − 0.082 0.001
TDI − 0.872 < 0.001 −0.401 − 0.575 a − 0.295 0.002
Table 3.  Linear regression values show the ageing olfactory loss in USH1 patients, compared with 
normative data. TDI = composite score of T, D and I olfactory tests. T = threshold test; D = discrimination test; 
I = Identification test. All the p-values remained statistically significant either by the Holm’s or the Benjamini-
Hosper correction for multiple comparisons.
Healthy subjects age dependent 
olfactory decrease
Usher Syndrome age dependent 
olfactory decrease
Mean 95% CI p Mean 95% CI P
T − 0.032 − 0.058 to − 0.006 0.017 −0.156 − 0.225 to − 0,087 < 0.001
D − 0.018 − 0.037 to + 0.001 0.067 − 0.106 − 0.157 to − 0.056 0.001
I − 0.025 − 0.040 to − 0.010 0.001 −0.102 − 0.142 to − 0.062 < 0.001
TDI − 0.075 − 0.112 to − 0.038 < 0.001 −0.326 − 0.476 to − 0.177 < 0.001
Table 4.  Decreased olfactory function related to USH1 after adjusting for age related olfactory loss.  
TDI: composite score of T, D and I olfactory tests. T: threshold test; D: discrimination test; I: Identification test.; 
CI – confidence interval. Highlighted differences should be retained as statistically significant differences.
Figure 1. USH1 faster olfactory ageing decline, not expected by normal age olfaction decline (p < 0.001). 
USH1: Usher type 1. TDI: composite score of Sniffin’ Sticks olfaction test.
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all studies have found superior olfactory capabilities in the different olfaction areas46–48, but discrepancies are not 
surprising because most studies enrolled few patients, lacked matched-pair controls and did not use standardized 
and cultural validated olfactory testing procedures46,47,49,50. Patients with USH2 may have shown less significant 
differences because when a person is afflicted by combined visual and hearing impairment, it becomes more dif-
ficult for other sensory systems to compensate39.
The higher scores observed in younger patients with USH, in particular in USH1, may be a compensa-
tory olfactory effect of deaf-blindness. There is growing evidence that congenitally blind individuals out-
perform age- and gender matched, normally sighted persons in tactile, auditory and possibly also olfactory 
tasks39,41,44, but such effect is not seen in late-blindness patients41,45,51. Thus, our results are not surprising 
in view of the fact that both hearing and visual loss occur earlier and in a more severe manner in patients 
with USH144.
The number of cases used to perform each regression was different due to the sampling of such a rare dis-
ease, where patients with USH1 were 22 and USH2 43. In spite of the different number of cases used in both 
regressions, statistical power was similar thus both regressions are valid and comparable in terms of conclu-
sions achieved. The regression models showed a power superior to 91% in all comparisons performed. When the 
observed effect sizes are large (between 1.27 and 4.24), a nearly null type II error exists and the p-value achieved 
(p < 0.001) represent a true positive value between groups. The difference between patients with USH1 and USH2 
concerning TDI scores represent an effect size of 1.27 which means that the achieved a posteriori power with 
Figure 2. USH2 olfactory ageing decline comparing to the healthy population (p > 0.05). USH2: Usher type 
2. TDI: composite score of Sniffin’ Sticks olfaction test.
Age
STS P
Holm’s Correction 
(α)
Benjamini-Hochberg 
(α)<43yr ≥43yr
USH
T 10.4 ± 2.3 6.8 ± 3.2 −4.020 <0.001 0.017 0.017
D 11.8 ± 1.9 10.1 ± 2.0 0.093 0.926 0.050 0.050
I 13.6 ± 1.5 11.6 ± 2.6 −3.360 0.001 0.025 0.033
TDI 35.8 ± 4.8 29.7 ± 6.8 − 4.261 < 0.001
USH1
T 11.9 ± 1.7 4.9 ± 2.0 −3.915 <0.001 0.017 0.017
D 12.9 ± 1.2 8.4 ± 1.1 −3.112 <0.001 0.050 0.050
I 14.4 ± 1.0 10.2 ± 1.6 −3.201 <0.001 0.025 0.033
TDI 39.1 ± 3.5 24.9 ± 4.1 −3.120 <0.001
USH2
T 9 ± 1.9 7.5 ± 3.3 0.223 0.232 0.017 0.017
D 10.8 ± 1.9 10.4 ± 1.9 0.466 0.491 0.050 0.050
I 12.8 ± 1.6 11.9 ± 2.7 0.409 0.432 0.025 0.033
TDI 32.7 ± 3.8 30.7 ± 6.9 0.516 0.532
Table 5.  Olfaction scores comparing USH, USH1 and USH2 patients below and above 43 years old (mean 
age of USH1), after correcting for normal ageing decline. USH: Usher syndrome patients. USH1: Usher type 1 
patients. USH2: Usher type 2 patients. TDI: composite score of T, D and I olfaction tests. T: threshold test;  
D: discrimination test; I: Identification test. Highlighted differences should be retained as statistically significant 
differences, according to the alpha level presented either by the Holm’s or the Benjamini-Hochberg correction 
for multiple comparisons.
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a sample of 22 and 43 patients is 99.87%. Therefore, we must conclude there is no bias related to the different 
number of patients in each group and consequently, the observed dispersion is related to the olfactory features of 
patients with USH.
Data linking USH to a ciliopathy is grounded on histopathological and molecular studies24,27. Most of the USH 
proteins have been localized at or around ciliary photoreceptor structures in the retina (as well as other ciliated 
tissues, such as olfactory epithelium)14,21,52,53. On the other hand, a considerable body of evidence indicates that 
olfactory dysfunction might well be associated with ciliary disorders18,25,27,53,54. Proteins related to the USH have 
a periciliary localization and play a role in ciliogenesis and ciliary maintenance of olfactory cilia55. Furthermore, 
given the evidence linking ciliary abnormalities to USH- related pathology in the retina18,56, inner ear18,57, 
nasal27,52,58 and tracheal mucosa19,59,60, and sperm21, the consequences of a genetic olfactory cilia impairment21,24,52,56 
may well explain the faster decrease in olfaction seen in this study´s patients with USH1.
Although it is the biggest study on olfaction in patients with USH to our knowledge, the results must be 
regarded with caution until larger series confirm it. Consequently, and because of the rarity of USH, multicenter 
studies are needed to investigate olfactory function in these rare cases. Moreover, a possible supra-threshold effect 
may have not been studied due to the possible ceiling effect of Sniffin’ Sticks, something that was not explored41.
Olfactory dysfunction should be considered in the spectrum of clinical manifestations associated with Usher 
syndrome. Patients with USH present better olfactory scores than controls, especially younger USH1. The olfac-
tion difference between USH1 and USH2, as well as the major decline in olfactory ability seen in USH1, but not in 
USH2, may contribute to distinguish USH types and represent an attractive tool for pre diagnostic screening due 
to the low cost and non-invasive nature of the procedure.
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